0001140361-24-017141.txt : 20240402 0001140361-24-017141.hdr.sgml : 20240402 20240402071035 ACCESSION NUMBER: 0001140361-24-017141 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240402 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 24812201 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 8-K 1 ef20025692_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): April 2, 2024

 
Roivant Sciences Ltd.
(Exact Name of Registrant as Specified in Charter)

Bermuda
001-40782
98-1173944
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
(Address of Principal Executive Offices, and Zip Code)

+44 207 400-3347
Registrant’s Telephone Number, Including Area Code

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share
  
ROIV
  
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.
Other Events.
 
Data Release

On April 2, 2024, Roivant Sciences Ltd. (“Roivant”) issued a press release announcing positive NEPTUNE study results for brepocitinib in non-anterior non-infectious uveitis, as well as authorization by Roivant’s board of directors for an up to $1.5 billion common share repurchase program, including the repurchase of all common shares held by Sumitomo Pharma Co., Ltd. (“Sumitomo”) for approximately $648.4 million. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item 8.01.

As described in the press release, Roivant will host a conference call and webcast to discuss the NEPTUNE results and its share repurchase program at 8:00 a.m. EDT on April 2, 2024.

Share Repurchase

Roivant’s board of directors has authorized a common share repurchase program, allowing for repurchases of Roivant common shares in an aggregate amount of up to $1.5 billion (excluding fees and expenses). The repurchase program will be funded with available cash and cash equivalents on hand and does not have an expiration date. The timing and total amount of common shares to be repurchased will depend on several factors, including the market price of the company’s common shares, general business, macroeconomic and market conditions and other investment opportunities. Under the repurchase program, purchases may be conducted through open market transactions, tender offers or privately negotiated transactions, including the use of trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Pursuant to the share repurchase program, on April 2, 2024 Roivant entered into a share repurchase agreement with Sumitomo to repurchase all 71,251,083 common shares held by Sumitomo at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million. The repurchase transaction with Sumitomo is expected to close on or about April 4, 2024.

The share repurchase program may be suspended or discontinued at any time. There can be no assurances as to how many additional common shares the company will repurchase under the program, if any, or at what prices any purchases will be made.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
  
Description of Exhibit
 
Press Release dated April 2, 2024
104
  
Cover Page Interactive Data File (embedded with Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.
  
     
By:
/s/ Matt Maisak
  
 
Name: Matt Maisak
  
 
Title: Authorized Signatory
  
     
Dated: April 2, 2024
  


EX-99.1 2 ef20025692_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
 

 •
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 million

•
Sumitomo Pharma repurchase reduces shares outstanding by 9%

•
In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoint

•
29% of subjects receiving brepocitinib 45 mg and 44% of subjects receiving brepocitinib 15 mg met the pre-specified primary efficacy endpoint of Treatment Failure at week 24 (lower failure rates reflect greater treatment benefit).  The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm

•
All secondary efficacy endpoints were also positive and dose responsive, including measurements of potential benefit on prevention and treatment of uveitic macular edema

•
NEPTUNE represents the seventh positive Phase 2 study for brepocitinib with over 1,400 subjects and patients treated with brepocitinib in clinical trials. Brepocitinib was generally safe and well-tolerated in the study; no new safety and tolerability signals were identified

•
Brepocitinib is well positioned to support a potential multi-blockbuster franchise in specialty autoimmunity with an ongoing pivotal study in dermatomyositis on track to read out in calendar year 2025 and expected initiation of a pivotal program in NIU in the second half of calendar year 2024

•
Roivant will host an investor call to discuss the updates at 8 a.m. EDT on Tuesday, April 2, 2024
 
BASEL, Switzerland and LONDON and NEW YORK, April 2, 2024 (GLOBE NEWSWIRE) – Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. Roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company’s common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is approximately $648.4 million and will reduce Roivant’s shares outstanding as of February 9, 2024 by approximately 9%.

“The striking NIU data underscore Roivant’s continued commitment to developing effective medicines in underserved indications with high unmet need, such as for these patients who are at risk of blindness. We are extremely pleased to share these positive data. We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma. This transaction along with further potential buybacks reduces shareholder concentration and efficiently retires shares, increasing our continuing shareholders’ exposure to developments in NIU and to the rest of our upcoming clinical data and company progress,” said Matt Gline, CEO of Roivant.
 
The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily. Patients, physicians, and the study team were blinded to dose. All subjects received a 60 mg/day prednisone burst at study entry for two weeks and were tapered off prednisone per protocol by week 8 (six-week steroid taper). Subjects were evaluated for Treatment Failure, a registrational composite endpoint comprising multiple measures of ocular inflammation and visual acuity, as well as discontinuation due to intercurrent events or initiation of rescue therapy. The study’s primary efficacy endpoint was the Treatment Failure rate at week 24.

At week 24, 29% (5/17) of subjects in the brepocitinib 45 mg arm and 44% (4/9) of subjects in the brepocitinib 15 mg arm met Treatment Failure criteria, with lower failure rates reflecting greater treatment benefit.  The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm.  These observed results represent approximately twice the observed benefit as seen in the corresponding registrational study for the only approved non-steroidal therapy in NIU.
 
All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive. Of patients in the brepocitinib 45 mg arm who met the threshold for uveitic macular edema at baseline, 43% achieved resolution of macular edema by week 24. No patients in the brepocitinib 45 mg arm who entered the study without macular edema developed macular edema by week 24.

Safety and tolerability were consistent with prior clinical studies of brepocitinib, with no new safety or tolerability signals identified. Brepocitinib has been dosed in over 1,400 subjects and patients with a safety profile that appears consistent with approved and widely prescribed JAK inhibitors. Additional safety and efficacy data will be presented at a future medical conference. 
 
“Non-infectious uveitis is a devastating disease that can lead to severe visual impairment and contribute to tens of thousands of cases of legal blindness in the United States each year, including many instances of irreversible blindness,” said Quan Dong Nguyen, MD, MSc, FARVO, FASRS, NEPTUNE investigator and Professor of Ophthalmology at the Byers Eye Institute, and Professor of Medicine and Pediatrics at Stanford University School of Medicine. “Current treatment options provide inadequate benefits to many patients; thus, novel pharmacotherapeutic agents with better efficacy and more convenient methods of administration are urgently needed. Brepocitinib’s striking results on multiple endpoints of clinical significance position the drug to become a potentially transformative once-daily oral therapy for this debilitating disease and reinforce the distinctive mechanistic benefits of dual TYK2/JAK1 inhibition for highly inflammatory autoimmune diseases with multiple pathogenic cytokines, such as non-infectious uveitis.”
 
“The NEPTUNE study was designed to minimize likelihood of false signals of benefit, by tapering patients with active disease from 60 mg/day of prednisone to 0 mg/day in just six weeks, more than twice as fast as steroid tapers in precedent studies,” said Ben Zimmer, CEO of Priovant. “Against that backdrop, we are thrilled to see a failure rate of only 29% in the brepocitinib 45 mg arm, better than any precedent study was able to achieve even with more lenient tapers. The magnitude and consistency of dose-dependent benefit across multiple independent measurements of inflammation, visual acuity, and macular edema give us high confidence heading into Phase 3. The results further point to a potentially highly differentiated product profile for brepocitinib in NIU—an orphan indication with high prevalence, severe morbidity, and few other therapies approved or in development.”
 
Priovant intends to initiate a Phase 3 program in NIU in the second half of calendar year 2024. The company would like to thank all of the investigators and patients who participated in the NEPTUNE study.

The ongoing Phase 3 study evaluating brepocitinib in dermatomyositis is expected to be fully enrolled in the third calendar quarter of 2024, with data expected in calendar year 2025.
 
Share Repurchase Program & Sumitomo Pharma Repurchase

Roivant’s board of directors has authorized a common share repurchase program, allowing for repurchases of Roivant common shares in an aggregate amount of up to $1.5 billion. The repurchase program will be funded with available cash and cash equivalents on hand and does not have an expiration date. The timing and total amount of common shares to be repurchased will depend on several factors, including the market price of the company’s common shares, general business, macroeconomic and market conditions, and other investment opportunities. Under the repurchase program, purchases may be conducted through open market transactions, tender offers or privately negotiated transactions, including the use of trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Pursuant to the share repurchase program, on April 2, 2024, Roivant entered into a share repurchase agreement with Sumitomo Pharma to repurchase all 71,251,083 common shares held by Sumitomo Pharma at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million. The repurchase transaction with Sumitomo Pharma is expected to close on or about April 4, 2024.

The repurchase program may be suspended or discontinued at any time. There can be no assurances as to how many additional common shares the company will repurchase under the program, if any, or at what prices any purchases will be made.

Investor Call

An investor call and webcast will be held at 8 a.m. EDT on April 2, 2024, to discuss the Phase 2 NEPTUNE study results for brepocitinib in NIU and Roivant’s share repurchase program. To access the conference call by phone, please register online using this registration link. The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

About Priovant

Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company’s lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1.  Through dual TYK2/JAK1 inhibition, brepocitinib is able to distinctively suppress key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL6, IL12, and IL23—with a single, targeted therapy. Brepocitinib has generated positive data in seven Phase 2 studies with oral once-daily administration. Brepocitinib is currently being evaluated in a Phase 3 program for dermatomyositis and is entering a Phase 3 program for non-infectious uveitis.

About Roivant
 
Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Today, Roivant’s pipeline includes VTAMA®, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (“FcRn”) in development across several IgG-mediated autoimmune indications; brepocitinib, a novel TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in addition to other clinical stage molecules. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.

Roivant Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about potential share repurchases, the clinical and therapeutic potential of our products and product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
 
Contacts:

Investors
Roivant Investor Relations
ir@roivant.com

Media
Stephanie Lee
Roivant Sciences
stephanie.lee@roivant.com 

Research
Daniel Herz-Roiphe
Priovant Therapeutics
daniel.herz-roiphe@priovanttx.com


 EX-101.SCH 3 roiv-20240402.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 roiv-20240402_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 roiv-20240402_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information
Apr. 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 02, 2024
Entity File Number 001-40782
Entity Registrant Name Roivant Sciences Ltd.
Entity Central Index Key 0001635088
Entity Incorporation, State or Country Code D0
Entity Tax Identification Number 98-1173944
Entity Address, Address Line One 7th Floor
Entity Address, Address Line Two 50 Broadway
Entity Address, City or Town London
Entity Address, Country GB
Entity Address, Postal Zip Code SW1H 0DB
City Area Code 207
Local Phone Number 400-3347
Title of 12(b) Security Common Shares, $0.0000000341740141 per share
Trading Symbol ROIV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( % Y@E@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !0.8)8A=[+K^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2@,Q$(9?17+?G60K"F&;B^*I!<&"XBTDTS:XR89D9+=O;W9MMX@^@)!+9OY\ M\PVD-5&:/N%SZB,F"1M-6F8@%5621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M % Y@ECM]CY#800 "P1 8 >&PO=V]R:W-H965T&UL MC9AA;^(X$(;_BI4[G>ZDMM@A%-H#)$JWNVB[+5>XK72G^V 2 ]8F<=8VI?S[ M&R/!E/WK'I;Y7^9M9"6/*:Q*D9>&MKL^M6RX1KD7!SH3*1 MPI6ET@FW<*I7+9-IP:,\*(E;/J67K83+U!OV\^^F>MA7&QO+5$PU,9LDX7IW M(V*U'7C,>_OB2:[6UGW1&O8SOA(S8?_.IAK.6J5*)!.1&JE2HL5RX(W8]8W? M<0'YB*]2;,W!,7&/LE#JFSN91 ./.B(1B] Z"0X?+V(LXM@I Q?5+;3V+_0#E@J&*3_R?;8FP0 M>"3<&*N2?3 0)#(M/OGK/A&' 9TC ?X^P,^YBQOEE+?<\F%?JRW1;C2HN8/\ M4?-H@).IFY69U7!50IP=WJIP TFVA*<1^9!::7=DDA:S#5GKMRS K82T"\!_5RO?41OK%Z$)O^.%L9JF,+_ZH@* MA:!>P=7UM%*X1^D5XP]]^89?T3X2O7?*U,?4J@?-=)NK@\/#>^6<$ M(B@A E1E! 113G$7\U4=!1Z_Y+$1"$>GY.B=@D"Z'KJ' -2MEY0+L]'^'IECS=4WB>Q$JZTH:D M/?"D-E.XSI.2+RYZ%DJ1AL*0>QM=('R]DJ]W"M\8IE/S&$PA$J_DL]C5$>)* M%-)VV>[07@_!NBJQKD[!FJ2ATIG2N4N=D9F%*B-*D[': "]@JZ@VE[CX+44( M&:T\E9["..>O9!)!_N12ACDH4G@-DE>]<\:Z[:L >Q78@>NS4PA'402.:,[> M#L@]C"./:6WJ&B2[=@WNHY3& "O79ZAIXX#SK:H%Q"4[E-QHQ:,MWV&(E?$S MW+K?(X[=&93@7&WK^R8N=Z_2Z'W#_9&LZ@8,M_.?R(J7HA8*5_IX@P%5;8'A M;OX>:*J,!4_Y1V9'7]0&Q=DS^T3H+8I7=0:&VWH^9B7"C(5NU M6+C26"4)..!LS:$&SLBO]((6?^V =0/* D8R6.D9=QU#KQH%P\U\KGDDTQ69 M[9*%BFN)<8&GQ\E7; 5;]0,?-^^WK)$/K^&:IRMQM-4W"#V,9K>COS"FJ@/X M)W6 #XG0*Y>ECZ #@ZSE/&T=GX;!)O6D/[!BA\WZF?(E16I8TDVZ;YUFEHD M7*@1J?)Z'S?GF8IE**U+U!=8:6C):PNJ0:61IW)X'_?EJ1;G(:3'K?B*W0=L M .#M>5PNZSVC0:^1K+)Z'S?FG\@FQFR K!$0EST*V#K8^[K?$;YP5\^&Q&() M0O2B"[JZV)H7)U9E^79XH2QLKO/#M># Y@; ]:52]NW$[;#+'TB&_P-02P,$ M% @ 4#F"6)^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP M$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:') MW3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG M;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X], M;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._] MN/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^ MR=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KX MK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P< MT:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<< MGB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8 MGKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U] M;4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ 4#F"6)>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@ MR*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_A^[<#K3P&]'@!6^AC(,=D",Y1]X MVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AH MQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL M(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ 4#F"6"0>FZ*M ^ $ M !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;* M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( % Y@EAED'F2&0$ M ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@ MIAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1 M?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI M>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UP MZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T M,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^ MD&PO=&AE;64O=&AE;64Q M+GAM;%!+ 0(4 Q0 ( % Y@ECM]CY#800 "P1 8 " M@0T( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !0.8)899!YDAD! #/ P $P M @ &Z$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" $ %% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://roivant.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20025692_8k.htm roiv-20240402.xsd roiv-20240402_lab.xml roiv-20240402_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20025692_8k.htm": { "nsprefix": "roiv", "nsuri": "http://roivant.com/20240402", "dts": { "inline": { "local": [ "ef20025692_8k.htm" ] }, "schema": { "local": [ "roiv-20240402.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "roiv-20240402_lab.xml" ] }, "presentationLink": { "local": [ "roiv-20240402_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://roivant.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240402to20240402", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20025692_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240402to20240402", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20025692_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001140361-24-017141-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-017141-xbrl.zip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ef20025692_8k_htm.xml IDEA: XBRL DOCUMENT 0001635088 2024-04-02 2024-04-02 false 0001635088 8-K 2024-04-02 Roivant Sciences Ltd. D0 001-40782 98-1173944 7th Floor 50 Broadway London SW1H 0DB GB 207 400-3347 false false false false Common Shares, $0.0000000341740141 per share ROIV NASDAQ false